domingo, 11 de noviembre de 2012

Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease - Executive Summary | AHRQ Effective Health Care Program

Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease - Executive Summary | AHRQ Effective Health Care Program



Insufficient Evidence Exists on Biomarkers to Detect Iron Deficiency Anemia in Patients with Kidney Disease

A new research review from AHRQ evaluates the evidence on the comparative effectiveness and accuracy of using biomarkers to identify iron deficiency anemia in patients with kidney disease.  No single laboratory test that examines biomarkers of iron status can determine iron deficiency, and more evidence is needed to determine the comparative accuracy of various biomarker combinations for diagnosing iron deficiency, the review found.  Overall, the strength of evidence supporting these conclusions is low, particularly related to children and non-hemodialysis patients.  Clinical uncertainty also remains about the use of newer biomarkers in the assessment of iron status and management of iron deficiency in patients with stages 3 – 5 chronic kidney disease.  Select to access Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late Stage Chronic Kidney Disease.

No hay comentarios: